2021
Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer.
Takvorian S, Parikh R, Vader D, Wileyto E, Clark A, Lee D, Goyal G, Rocque G, Dotan E, Geynisman D, Phull P, Spiess P, Kim R, Davidoff A, Gross C, Miksad R, Calip G, Shulman L, Mamtani R, Hubbard R. Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer. Journal Of Clinical Oncology 2021, 39: 1528-1528. DOI: 10.1200/jco.2021.39.15_suppl.1528.Peer-Reviewed Original ResearchAdvanced solid cancersTreatment initiationAdvanced cancer diagnosisAdvanced cancerSolid cancersCancer typesCox proportional hazards modelCOVID-19 pandemicSystemic therapy initiationSystemic treatment initiationTimely care deliveryDe novo cancerDe novo diseaseAdvanced breast cancerCancer diagnosisLife-prolonging therapiesProportional hazards modelInterrupted time series analysisDe-identified databaseProbability of treatmentNovo diseaseTherapy initiationNovo cancerPerformance statusClinical outcomes
2020
Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.Peer-Reviewed Original ResearchMetastatic prostate cancerSystemic therapy initiationTherapy initiationNGS test resultsNGS testingSystemic therapyMetastatic diagnosisNGS testsProstate cancerCommon systemic therapySystemic therapy selectionRetrospective observational studyNext-generation sequencing testDe-identified databaseMPC patientsTherapy startClinical outcomesMedian timeTherapy changesTreatment choiceObservational studyTherapy selectionGenomic classifierPatientsTherapy
2019
Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice.
Parikh R, Galsky M, Gyawali B, Riaz F, Kaufmann T, Cohen A, Adamson B, Gross C, Meropol N, Mamtani R. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice. Journal Of Clinical Oncology 2019, 37: 395-395. DOI: 10.1200/jco.2019.37.7_suppl.395.Peer-Reviewed Original ResearchAdvanced urothelial cell carcinomaPoor performance statusEnd of lifeSystemic therapyDay of deathQuarterly proportionPoor PSStudy periodFlatiron Health databaseSystemic therapy initiationCheckpoint inhibitor therapyFavorable toxicity profileUrothelial cell carcinomaDays of lifeSecular trend analysisChemotherapy initiationChemotherapy useCPI useReal-world practiceTherapy initiationInhibitor therapyPerformance statusPS 0Cell carcinomaNational guidelines